Lifitegrast Ophthalmic Solution 5.0% for Treatment of Dry Eye Disease: Overview of Clinical Trial Program

Lifitegrast Ophthalmic Solution 5.0% for Treatment of Dry Eye Disease: Overview of Clinical Trial Program

Dry eye disease (DED) is a common inflammatory disorder of the ocular surface. Millions of people are affected by DED worldwide. Lifitegrast is a novel drug designed to inhibit DED-associated ocular inflammation. Four clinical trials have shown that lifitegrast is well tolerated and effective in im...

Full description

Bibliographic Details
Main Authors:	Clara C Chan, C. Lisa Prokopich
Format:	Article
Language:	English
Published:	Canadian Society for Pharmaceutical Sciences 2019-01-01
Series:	Journal of Pharmacy & Pharmaceutical Sciences
Online Access:	https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/29895

Similar Items

Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
by: White DE, et al.
Published: (2019-11-01)

Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy
by: Godin MR, et al.
Published: (2017-05-01)

Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial
by: Nichols KK, et al.
Published: (2018-01-01)

Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial [Corrigendum]
by: Nichols KK, et al.
Published: (2018-05-01)

Dry eye syndrome: developments and lifitegrast in perspective
by: Lollett IV, et al.
Published: (2018-01-01)

Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort
by: Gonzalez AL
Published: (2018-10-01)

Lifitegrast: a novel drug for patients with dry eye disease
by: Stacy L. Haber, et al.
Published: (2019-08-01)

Real-World Experience with Lifitegrast Ophthalmic Solution (Xiidra®) in the US and Canada: Retrospective Study of Patient Characteristics, Treatment Patterns, and Clinical Effectiveness in 600 Patients with Dry Eye Disease
by: Hovanesian JA, et al.
Published: (2021-03-01)

Efficacy and safety of lifitegrast in the treatment of dry eye disease: a Meta-analysis
by: Ling Li, et al.
Published: (2020-10-01)

Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease
by: Semba CP, et al.
Published: (2016-06-01)

The Effect of Lifitegrast on Refractive Accuracy and Symptoms in Dry Eye Patients Undergoing Cataract Surgery
by: Hovanesian J, et al.
Published: (2020-09-01)

A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease
by: McMullin D, et al.
Published: (2021-09-01)

Longitudinal changes in dry eye symptoms and signs following lifitegrast therapy and relationship to tear osmolarity
by: Pepose JS, et al.
Published: (2019-03-01)

Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review
by: Atallah RT, et al.
Published: (2019-06-01)

Efficacy of rebamipide 2% ophthalmic solution in the treatment of dry eyes
by: Saurabh Shrivastava, et al.
Published: (2018-01-01)

Dry Eye Treatment with Topical Cyclosporine 0.1% in Chondroitin Sulfate Ophthalmic Emulsion
by: Matossian C, et al.
Published: (2021-05-01)

Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease
by: Burade V, et al.
Published: (2020-09-01)

Clinical utility of 3% diquafosol ophthalmic solution in the treatment of dry eyes
by: Koh S
Published: (2015-05-01)

Correction to: In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
by: John D. Sheppard, et al.
Published: (2019-02-01)

Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease
by: de Oliveira RC, et al.
Published: (2019-07-01)

Efficacy and safety of retinol palmitate ophthalmic solution in the treatment of dry eye: a Japanese Phase II clinical trial
by: Toshida H, et al.
Published: (2017-06-01)

Efficacy and Safety of Retinol Palmitate Ophthalmic Solution in the Treatment of Dry Eye: A Japanese Phase II Clinical Trial [Corrigendum]
by: Toshida H, et al.
Published: (2021-02-01)

Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye
by: Deveney T, et al.
Published: (2018-03-01)

Practical Guidance for the Use of Loteprednol Etabonate Ophthalmic Suspension 0.25% in the Management of Dry Eye Disease
by: Bian, Y., et al.
Published: (2022)

Review of hydroxypropyl cellulose ophthalmic inserts for treatment of dry eye
by: Nguyen T, et al.
Published: (2011-05-01)

Safety and efficacy of MIM D3 ophthalmic solutions in a randomized placebo controlled Phase 2 clinical trial in patients with dry eye
by: Meerovitch K, et al.
Published: (2013-06-01)

Assessment and Management of Dry Eye Patients for Non-Ophthalmic Healthcare Practitioners
by: Louis Tong MBBS, FRCS, PhD, et al.
Published: (2012-03-01)

Changes of tear film lipid layer thickness by 3% diquafosol ophthalmic solutions in patients with dry eye syndrome
by: Dong-Hyun Kang, et al.
Published: (2019-10-01)

Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal
by: Kashima T, et al.
Published: (2014-05-01)

Clinical observation of deproteinated extract of calf blood ophthalmic gel for dry eye
by: Ming Tan, et al.
Published: (2014-05-01)

The Effects of Rebamipide 2% Ophthalmic Solution Application on Murine Subbasal Corneal Nerves After Environmental Dry Eye Stress
by: Cem Simsek, et al.
Published: (2019-08-01)

Ophthalmic antiviral chemotherapy : An overview
by: Athmanathan Sreedharan, et al.
Published: (1997-01-01)

PERSIST: Physician&#39;s Evaluation of Restasis&reg; Satisfaction in Second Trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective review
by: Mah F, et al.
Published: (2012-11-01)

Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes
by: Shafiee A, et al.
Published: (2013-07-01)

Efficacy of protein-free calf blood extract ophthalmic gel for children dry eye
by: Jun Ouyang, et al.
Published: (2014-12-01)

Clinical analysis of diclofenac sodium eye drops combined with sodium hyaluronate eye drops for dry eye after ophthalmic surgery
by: Li-Ping Liu, et al.
Published: (2017-07-01)

Effects of 3% diquafosol sodium ophthalmic solution on higher-order aberrations in patients diagnosed with dry eye after cataract surgery
by: Inoue Y, et al.
Published: (2016-12-01)

Clinical effectiveness of diquafosol ophthalmic solution 3% in Korean patients with dry eye disease: a multicenter prospective observational study
by: Youngsub Eom, et al.
Published: (2021-10-01)

Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections
by: Darlene Miller
Published: (2008-03-01)

Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK
by: Wang XJ, et al.
Published: (2011-10-01)